Prognostic factors for CR at three months (N = 154 patients)
| Variable . | No. of patients considered . | P (RR, 95% CI) Univariate analyses4-150 . | P (RR, 95% CI) Multivariate analyses4-151 . | |
|---|---|---|---|---|
| N = 129 pts . | N = 69 pts . | |||
| Age | ||||
| As a continuous variable | 154 | .76 | — | — |
| Less than 45 y | 154 | .50 | — | — |
| Sex | 154 | .74 | — | — |
| CNS involvement | 154 | .99 | — | — |
| Myeloid markers‡ | 150 | .18 | — | — |
| Anthracycline4-153 | 154 | .10 | — | — |
| Leukocyte count | ||||
| As a continuous variable | 154 | .01 | — | — |
| Less than 25 × 109/L | 154 | .01 | .02 | .09 |
| 1.41 (1.07-1.86) | 2.53 (1.15-5.57) | 2.59 (0.86-7.75) | ||
| Cytogenetics | ||||
| Hyperploidy | 141 | .13 | — | — |
| Monosomy 7 | 141 | .37 | — | — |
| Additional abnormalities4-155 | 122 | .67 | — | — |
| Ph duplication4-155 | 122 | .33 | — | — |
| NN vs AN-AA | 141 | .05 | .14 | .15 |
| 1.48 (1.15-1.89) | 3.29 (0.68-15.9) | 5.06 (0.56-45.8) | ||
| bcr subtype: M-bcr vs m-bcr | 142 | .09 | .04 | .47 |
| 1.27 (0.99-1.62) | 2.52 (1.06-6.01) | 1.55 (0.47-5.10) | ||
| Early response to therapy4-154 | 81 | .03 | — | .05 |
| 1.59 (1.16-2.18) | 5.21 (1.03-26.4) | |||
| Variable . | No. of patients considered . | P (RR, 95% CI) Univariate analyses4-150 . | P (RR, 95% CI) Multivariate analyses4-151 . | |
|---|---|---|---|---|
| N = 129 pts . | N = 69 pts . | |||
| Age | ||||
| As a continuous variable | 154 | .76 | — | — |
| Less than 45 y | 154 | .50 | — | — |
| Sex | 154 | .74 | — | — |
| CNS involvement | 154 | .99 | — | — |
| Myeloid markers‡ | 150 | .18 | — | — |
| Anthracycline4-153 | 154 | .10 | — | — |
| Leukocyte count | ||||
| As a continuous variable | 154 | .01 | — | — |
| Less than 25 × 109/L | 154 | .01 | .02 | .09 |
| 1.41 (1.07-1.86) | 2.53 (1.15-5.57) | 2.59 (0.86-7.75) | ||
| Cytogenetics | ||||
| Hyperploidy | 141 | .13 | — | — |
| Monosomy 7 | 141 | .37 | — | — |
| Additional abnormalities4-155 | 122 | .67 | — | — |
| Ph duplication4-155 | 122 | .33 | — | — |
| NN vs AN-AA | 141 | .05 | .14 | .15 |
| 1.48 (1.15-1.89) | 3.29 (0.68-15.9) | 5.06 (0.56-45.8) | ||
| bcr subtype: M-bcr vs m-bcr | 142 | .09 | .04 | .47 |
| 1.27 (0.99-1.62) | 2.52 (1.06-6.01) | 1.55 (0.47-5.10) | ||
| Early response to therapy4-154 | 81 | .03 | — | .05 |
| 1.59 (1.16-2.18) | 5.21 (1.03-26.4) | |||
RR indicates relative risk for being in complete remission at 3 months; CI, confidence interval; CNS, central nervous system; Ph, Philadelphia chromosome; M-bcr, major breakpoint cluster region; and m-bcr, minor breakpoint cluster region.
Using the Fisher exact test for binary variables and a univariate logistic model for continuous variables.
Using a multivariate logistic model.
Defined as the coexpression of CD34, CD33, and CD13 antigens.
Anthracycline randomly allocated for the induction course.
Comparisons were performed in the 122 patients with Philadelphia chromosome.
Evaluated on the day 8 bone marrow aspiration.